ORPHA:42
Medium chain acyl-CoA dehydrogenase deficiency
Also known as: ACADM deficiency · Carnitine deficiency secondary to medium-chain acyl-CoA dehydrogenase deficiency · MCAD deficiency · MCADD · Medium chain acyl-coenzyme A dehydrogenase deficiency
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
1,789
92.6th percentile
Trials
10
Interventional, condition-specific
Researchers
1,466
Distinct authors in sample
Gene link
ACADM
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Medium chain acyl-CoA dehydrogenase (MCAD) deficiency (MCADD) is an inborn error of fatty acid oxidation characterized by a rapidly crisis, often presenting as hypoketotic , lethargy, vomiting, and coma, which can be fatal in the absence of emergency medical intervention.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008721
- MeSH:C536038
- OMIM:201450
- UMLS:C0220710
- NCIT:C84538
Additional Mondo synonyms (7)
Acyl-CoA dehydrogenase, medium chain, deficiency of · MCAD · acyl-CoA dehydrogenase, medium-chain deficiency · medium chain acyl-CoA dehydrogenase deficiency · medium chain acyl-coenzyme A dehydrogenase deficiency · medium-chain acyl-CoA dehydrogenase deficiency · medium-chain acyl-Coenzyme A dehydrogenase deficiency
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — ACADM
- LiteraturePresent
1,789 matched papers (824 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
10 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (ACADM).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,789
1,789 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,789 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
824 in the last 10 years · medium confidence · 92.6th percentile (publications denominator)
Phrase hits: 1,789 · MeSH hits: 0
Who's working on it?
1,466
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Derks TGJ6 papers · 2025
Division of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, 9718 GZ Groningen, The Netherlands.
Papers in Europe PMC - 02Moreira S5 papers · 2025
Internal Medicine Department, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
Papers in Europe PMC - 03Wang Y5 papers · 2026
Nanjing Maternal and Child Health Care Hospital, Nanjing, China.
Papers in Europe PMC - 04Bakker BM4 papers · 2026
Laboratory of Paediatrics, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands. b.m.bakker01@umcg.nl.
Papers in Europe PMC - 05Bonham JR4 papers · 2026
Pharmacy, Diagnostics and Genetics, Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK.
Papers in Europe PMC - 06Domingues MR4 papers · 2025
CESAM - Centre for Environmental and Marine Studies, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; Mass Spectrometry Center, LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal. Electronic address: mrd@ua.pt.
Papers in Europe PMC - 07Domingues P4 papers · 2025
CESAM - Centre for Environmental and Marine Studies, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.
Papers in Europe PMC - 08Garbade SF4 papers · 2025
Department of Pediatrics I, Division of Pediatric Neurology and Metabolic Medicine, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
Papers in Europe PMC - 09Goracci L4 papers · 2025
Department of Chemistry, Biology and Biotechnology, University of Perugia (Perugia), Italy.
Papers in Europe PMC - 10Guerra IMS4 papers · 2025
CESAM - Centre for Environmental and Marine Studies, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; Mass Spectrometry Center, LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
10
interventional trials for this specific condition
10 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 3 trials are registered for acyl-CoA dehydrogenase deficiency, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
10 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 91.7th percentile).
medium confidence · 91.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
10 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06773026·RECRUITING·Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency·Matched via name phrase
- NCT06623032·RECRUITING·Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy Individuals
Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency·Matched via name phrase
Broader category: acyl-CoA dehydrogenase deficiency
3
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Medium chain acyl-CoA dehydrogenase deficiency" OR "ACADM deficiency" OR "Carnitine deficiency secondary to medium-chain acyl-CoA dehydrogenase deficiency" OR "MCAD deficiency" OR "MCADD" OR "Medium chain acyl-coenzyme A dehydrogenase deficiency" OR "Acyl-CoA dehydrogenase, medium chain, deficiency of" OR "acyl-CoA dehydrogenase, medium-chain deficiency" OR "medium-chain acyl-CoA dehydrogenase deficiency" OR "medium-chain acyl-Coenzyme A dehydrogenase deficiency"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Medium chain acyl-CoA dehydrogenase deficiency" OR "ACADM deficiency" OR "Carnitine deficiency secondary to medium-chain acyl-CoA dehydrogenase deficiency" OR "MCAD deficiency" OR "MCADD" OR "Medium chain acyl-coenzyme A dehydrogenase deficiency" OR "Acyl-CoA dehydrogenase, medium chain, deficiency of" OR "acyl-CoA dehydrogenase, medium-chain deficiency" OR "medium-chain acyl-CoA dehydrogenase deficiency" OR "medium-chain acyl-Coenzyme A dehydrogenase deficiency" OR "ACADM"
Recall-expansion terms: ACADM
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 10 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"acyl-CoA dehydrogenase deficiency"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MCAD
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T12:12:37.260Z
